Skip to main content

European Journal of Pharmaceutics and Biopharmaceutics

  • ISSN: 0939-6411

Editor-In-Chief: Breunig

Next planned ship date: April 30, 2024

  • 5 Year impact factor: 5.3
  • Impact factor: 4.9

Official Journal of the International Association for Pharmaceutical Technology The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publicatio… Read more

Subscription options

Next planned ship date:
April 30, 2024

Institutional subscription on ScienceDirect

Request a sales quote
Official Journal of the International Association for Pharmaceutical Technology

The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.

Topics covered include for example:

Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)

Aspects of manufacturing process design

Biomedical aspects of drug product design

Strategies and formulations for controlled drug transport across biological barriers

Physicochemical aspects of drug product development

Novel excipients for drug product design

Drug delivery and controlled release systems for systemic and local applications

Nanomaterials for therapeutic and diagnostic purposes

Advanced therapy medicinal products

Medical devices supporting a distinct pharmacological effect



"The Rules of 3"

The Editors and Editorial board have developed the "Rules of 3". Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work:
1. The paper must report on novel findings that are not merely an unprecedented combination of known aspects in pharmaceutics and biopharmaceutics of major importance.
2. A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented.
3. The study described in the manuscript must not merely confirm the state of the art in the field of pharmaceutics and biopharmaceutics, but advance it.